speak and had great difficulty in swallowing. There were no involuntary movements, but the limbs showed a severe degree of rigidity.
On examination of the eyes characteristic Kayser-Fleischer rings were found and a confident diagnosis of Wilson's disease was made. This was confirmed by the biochemical findings of low serum copper, low serum caeruloplasmin and raised urinary copper clearance (Table 1) . Liver function tests were normal apart from a marginally elevated alkaline phosphatase to 149 u/l (normal 35-105). Liver biopsy showed a marked increase in fibrous tissue and some nodular degeneration. The copper content of this tissue was not estimated.
The family tree is shown in Fig. 1 . A feature of particular interest is the occurrence of this condition in one of identical twins. Confirmation of identical genotypes was obtained by a detailed comparison of blood groups ( Treatment was commenced with d-penicillamine, 2 grams daily. Fig. 2 shows the increased clearance of copper following treatment. Clinical response has been disappointing. During the first three months of treatment there was some improvement in swallowing and after 18 months he is able to walk with help. However, he remains severely disabled and still unable to speak.
CASE 2 BM AGED 24 FEMALE
This young woman, who works as a clerk, presented with a history of unsteadiness on her feet and frequent falls, over a period of six months. The unsteadiness had become gradually worse and she had also experienced difficulty with writing, and drinking from a cup, because of shaking hands. On examination, she was euphoric and had a variable coarse tremor of the upper limbs at rest. It was made worse by voluntary movement and tended to become quite violent at times of excitement. She is right handed and this side was more severely affected. Tone was normal and there was no weakness. Her gait was ataxic and at times this became so severe that she almost fell. There was no nystagmus.
Initially a diagnosis of multiple sclerosis was considered likely, but examination of the eyes again showed the diagnostic Kayser-Fiescher rings of Wilson's disease. Biochemical screening confirmed the abnormal copper metabolism. She has three siblings, none are affected clinically.
Treatment was started with d-penicillamine 2 grams daily. There was a good biochemical response ( Fig. 3 ) and clinically her condition also improved. However, following discharge from hospital compliance was poor despite reduction of dosage to 500 mg daily. She developed nausea and a skin rash, and had one episode of jaundice, probably haemolytic type (this occurred while she was at home and confirmatory tests were not obtained).
Her clinical condition had deteriorated markedly by the end of 1981 and a further attempt was made to achieve a therapeutic dose of penicillamine using steroid cover. Unfortunately side effects, particularly nausea proved again troublesome and the drug had to be abandoned.
In February, 1982 triethylene tetramine dihydrochloride (Trien) was introduced at a dose of 600 mg daily increasing to 1500 mg daily and this has been successful in maintaining a good urinary copper clearance ( Fig. 3) It is of note that heterozygote carriers show biochemical changes in the same direction as affected individuals but usually to a less marked degree.3 This is seen in Table 1 where A. G.'s parents, who must be heterozygotes, have mildly abnormal or borderline normal values. The siblings, other than his twin, have at least one mildly abnormal change and may be heterozygotes. The ranges of biochemical values for affected individuals and heterozygotes are so wide that they can over-lap and this sometimes makes it difficult to differentiate between an affected presymptomatic individual who needs treatment and a carrier who does not.
Walshe suggests that in such cases a liver biopsy should be carried out for histological examination and copper estimation. However, the latter is difficult with a small amount of biopsy material and histochemical methods have often been found to be unreliable.8 It was also our experience with the liver biopsy from Case 2 that several histochemical techniques failed to demonstrate copper despite characteristic histological changes both by light and electron microscopy.
Treatment is designed to promote the mobilization and excretion of excess copper deposited in the tissues. The drug of choice is d-penicillamine, a chelating agent introduced in 1956.9 The clinical results can be very rewarding provided treatment is not delayed until neurological damage is irreversible. This is presumably the situation in our first case, although improvement may sometimes be delayed for a year or more after the initiation of treatment.3 Toxic reactions to penicillamine are not uncommon; these include urticaria and other skin rashes, nausea, anorexia, vomiting, fever, thrombocytopenia with or without leucopenia and a collagen disease-like reaction. Other less common signs of toxicity are mouth ulceration, pyridoxine deficiency, skin fragility, nephrotic syndrome, haemolytic anaemia and Goodpasture's syndrome.
Fortunately a newer drug, triethylene tetramine dihydrochloride (Trien) was introduced in 196910 and has been shown to be an equally effective chelating agent although acting in a slightly different way." Certainly in Case 2 the effect of the preparation in producing copper excretion was excellent (Fig. 3) 
